The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients (Q34420283)

2 August 2017

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients (English)

1 reference

2 August 2017

1 reference

0 references

van Megen HJ

1

1 reference

2 August 2017

Westenberg HG

2

1 reference

2 August 2017

den Boer JA

3

1 reference

2 August 2017

Slaap B

4

1 reference

2 August 2017

van Es-Radhakishun F

5

1 reference

2 August 2017

Pande AC

6

1 reference

2 August 2017

1 February 1997

1 reference

2 August 2017

1 reference

2 August 2017

129

1 reference

2 August 2017

243-248

1 reference

2 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s002130050186

2 August 2017

0 references

cites work

A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Anxiolytic effects of CCK-B antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Evaluation of the effects of PD 134308 (CI-988), A CCK-B antagonist, on the punished responding of squirrel monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

On the significance of cholecystokinin receptors in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Cholecystokinin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

The determination of cortisol in human plasma: evaluation and comparison of seven assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002130050186

Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9084062

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9084062

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S002130050186

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference